证券日报网讯 8月21日晚间，一品红发布公告称，公司第四届监事会第十次会议审议通过了《关于的议 案》。 （文章来源：证券日报） ...

针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。 （文章来源：北京商报） 8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营业收入5.84亿元，同比下 降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 ...

Growth - Teva Pharmaceutical reported a net profit of 38.01 million yuan in the first half of the year, a year-on-year increase of 1313.23% [1] - Qianfang Technology achieved a net profit of 170 million yuan, up 1287.12% year-on-year [1] - Tianyu Digital Science and Technology recorded a net profit of 23.62 million yuan, reflecting a 453.67% increase [1] - Suzhou Gude reported a net profit of 43.70 million yuan, up 310.28% year-on-year [1] - Sainuo Medical achieved a net profit of 13.84 million yuan, an increase of 296.54% [1] - Runfeng Co., Ltd. reported a net profit of 556 million yuan, up 205.62% year-on-year [1] - Guodian Nanzi achieved a net profit of 159 million yuan, reflecting a 197.03% increase [1] - Ruijie Networks reported a net profit of 452 million yuan, up 194% year-on-year [1] - Zhongjing Technology achieved a net profit of 25.74 million yuan, an increase of 144.05% [1] - China National Materials Technology reported a net profit of 999 million yuan, up 114.92% year-on-year [1] - Lante Optics achieved a net profit of 103 million yuan, reflecting a 110.27% increase [1] - Yidao Information reported a net profit of 11.41 million yuan, up 96.02% year-on-year [1] - Qianzhao Optoelectronics achieved a net profit of 69.23 million yuan, an increase of 88.04% [1] - Ruile New Materials reported a net profit of 166 million yuan, up 74.22% year-on-year [1] - Lvtian Machinery achieved a net profit of 140 million yuan, reflecting a 64.36% increase [1] - Mega Chip Color reported a net profit of 110 million yuan, up 48.83% year-on-year [1] - Jiaojian Co., Ltd. achieved a net profit of 113 million yuan, an increase of 48.66% [1] - Huhua Electronics reported a net profit of 1.683 billion yuan, up 47.50% year-on-year [1] - Sany Heavy Industry achieved a net profit of 5.216 billion yuan, reflecting a 46% increase [1] - Goodix Technology reported a net profit of 431 million yuan, up 35.74% year-on-year [1] - Allwinner Technology achieved a net profit of 161 million yuan, an increase of 35.36% [1] - Bichu Electronics reported a net profit of 640 million yuan, up 30.32% year-on-year [1] - Ganneng Co., Ltd. achieved a net profit of 438 million yuan, reflecting a 29.39% increase [1] - Weigao Medical reported a net profit of 492 million yuan, up 28.07% year-on-year [1] - GoerTek achieved a net profit of 1.417 billion yuan, reflecting a 15.65% increase [1] - Huason Pharmaceutical reported a net profit of 53.95 million yuan, up 14.27% year-on-year [1] - Gaoxin Development achieved a net profit of 66.92 million yuan, an increase of 14.06% [1] - Shanghai Jahwa reported a net profit of 266 million yuan, up 11.66% year-on-year [1] Stable Growth - Hangcha Group reported a net profit of 1.121 billion yuan, reflecting an increase of 11.38% year-on-year [2] - Dong'e Ejiao achieved a net profit of 818 million yuan, up 10.74% [2] - Beikong Technology reported a net profit of 54.31 million yuan, an increase of 10.59% [2] - Hongxin Electronics achieved a net profit of 53.99 million yuan, up 9.85% year-on-year [2] - Huace Testing reported a net profit of 467 million yuan, reflecting a 7.03% increase [2] - Samsung Medical achieved a net profit of 1.230 billion yuan, up 6.93% year-on-year [2] - Jiangzhong Pharmaceutical reported a net profit of 522 million yuan, reflecting a 5.80% increase [2] - Hualing Cable achieved a net profit of 63.64 million yuan, up 4.74% year-on-year [2] - Kuaijishan reported a net profit of 93.88 million yuan, reflecting a 3.41% increase [2] - Laishen Tongling achieved a net profit of 60.61 million yuan, turning from loss to profit [2] - Yunnan Geology reported a net profit of 22.15 million yuan, turning from loss to profit [2] - Shandong Steel achieved a net profit of 1.253 million yuan, turning from loss to profit [2] Decline and Loss - Zhongtian Rocket reported a net profit of 394,460 yuan, a year-on-year decrease of 80.74% [2] - Liuhua Co., Ltd. achieved a net profit of 344,280 yuan, down 78.01% year-on-year [2] - Qiaqia Food reported a net profit of 886.42 million yuan, a decrease of 73.68% [2] - Hangjin Technology achieved a net profit of 1.372 million yuan, down 58.38% year-on-year [2] - Taiping Bird reported a net profit of 7.771 million yuan, a decrease of 54.61% [2] - Canadian Solar reported a net profit of 731 million yuan, down 41.01% year-on-year [2] - Sinopec achieved a net profit of 21.483 billion yuan, a decrease of 39.8% [2] - Fulejia reported a net profit of 230 million yuan, down 32.54% year-on-year [2] - Palin Bio reported a net profit of 236 million yuan, down 27.89% [2] - Yiwei Lithium Energy achieved a net profit of 1.605 billion yuan, down 24.9% year-on-year [2] - Jinguang Electric reported a net profit of 42.34 million yuan, down 17.16% [2] - Hexing Co., Ltd. achieved a net profit of 107 million yuan, down 16.98% year-on-year [2] - Electric Investment Production and Financing reported a net profit of 459 million yuan, down 13.41% [2] - Tiantan Biological achieved a net profit of 633 million yuan, down 12.88% year-on-year [2] - Huali Group reported a net profit of 1.671 billion yuan, down 11.06% [2] - Zhongyou Engineering achieved a net profit of 470 million yuan, down 10.87% year-on-year [2] Further Losses - Chongda Technology reported a net profit of 222 million yuan, down 6.19% year-on-year [3] - Xinhua Department Store achieved a net profit of 86.01 million yuan, down 2.52% [3] - Zhuosheng Micro reported a net loss of 147 million yuan, turning from profit to loss [3] - Penghui Energy reported a net loss of 88.23 million yuan, turning from profit to loss [3] - Yipin Hong reported a net loss of 73.54 million yuan, turning from profit to loss [3] - Zhongbing Hongjian reported a net loss of 40.71 million yuan, turning from profit to loss [3] - Sanwei Xinan reported a net loss of 29.39 million yuan, turning from profit to loss [3] - Anyuan Coal reported a net loss of 290 million yuan [3] - Keda Xunfei reported a net loss of 239 million yuan [3] - Jishi Media reported a net loss of 23.2 million yuan [3] - Nanjing Chemical Fiber reported a net loss of 88.93 million yuan [3] - Guangsheng Tang reported a net loss of 66.69 million yuan [3] - Chutian Long reported a net loss of 39.77 million yuan [3]

针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。 北京商报讯（记者 丁宁）8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营 业收入5.84亿元，同比下降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 ...

（编辑 张昕） 报告期内，创新药领域进展尤为亮眼。一品红在研产品AR882（通用名：氘泊替诺雷）是一种高效选择性尿酸转运蛋白 （URAT1）抑制剂，具备降低血尿酸治疗痛风、溶解痛风石及治疗慢性肾病三大适应症。2025年3月，全球关键性Ⅲ期 REDUCE 2试验完成全部患者入组；6月，全球关键性Ⅲ期REDUCE 1试验已完成超过50%的患者入组；截至8月1日，AR882国 内Ⅲ期临床试验已入组超过50%的受试者，标志着该药全球同步研发的进程取得了又一重大进展。 基于AR882临床试验的阶段性成果，为了推动创新药AR882高效研发和快速上市。报告期内，公司子公司瑞奥生物以自有 资金680万美元受让控股子公司广州瑞安博少数股东Arthrosi 15.25%的股权。本次交易完成后，广州瑞安博将成为公司全资子公 司，公司持有AR882国内权益提升至100%，进一步拓展公司的核心竞争力和综合竞争优势。 本报讯 （记者李雯珊）8月21日晚间，一品红药业集团股份有限公司（以下简称"一品红"）披露2025年半年报。报告显 示，公司在2025年上半年整体保持稳健发展态势，公司围绕儿童药、慢病药及创新药持续深耕布局，研发管线不断拓 ...

中证报中证网讯(记者万宇)8月21日晚，一品红（300723）披露2025年半年报。公司围绕儿童药、慢病 药及创新药持续深耕布局，上半年实现营业收入5.84亿元，归属于上市公司股东的净利润-7354.22万 元。截至2025年6月30日，公司总资产49.81亿元，比2025年年初增加13.10%。公司创新药进展亮眼，上 半年获得10个药品注册批件，在研创新药AR882(通用名：氘泊替诺雷)全球研发加速，Ⅲ期临床试验已 完成全部受试者入组。 目前，一品红共有200个药品注册批件(含原料药登记号)，其中国家医保品种87个、国家基药品种26 个、国家中药保护品种1个。公司在儿童药领域现有27个注册批件，覆盖呼吸、抗感染、抗过敏、消化 等儿童常见病领域。在慢病药领域，公司现有67个注册批件，涵盖心脑血管疾病、泌尿系统疾病、消化 系统疾病等多个疾病治疗领域。公司还兼顾其他治疗领域的发展机会，报告期，公司在其他治疗领域新 增获批5个产品批件，进一步丰富了公司产品品类。 一品红在研产品AR882是公司与美国Arthrosi合作研发的1类创新药，是一种高效选择性尿酸转运蛋白 (URAT1)抑制剂，旨在通过抑制尿酸重吸收使尿液 ...

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has completed the enrollment of all participants in the global Phase III clinical trial for AR882, a novel drug for the treatment of gout and gout stones, developed in collaboration with Arthrosi Therapeutics, Inc. [1] Group 1 - AR882 (generic name: Deuricostat) is a first-class innovative drug that acts as a selective uric acid transporter (URAT1) inhibitor, aimed at normalizing uric acid salt excretion in urine and lowering serum uric acid (sUA) levels [1] - The company indirectly holds a 22.52% stake in Arthrosi [1] - The company, through its wholly-owned subsidiary Guangzhou Ruian Bo Pharmaceutical Technology Co., Ltd., holds 100% of the marketing authorization and all commercialization rights for AR882 in the Chinese region, including mainland China, Hong Kong, Macau, and Taiwan [1]

新增取得10个注册批件 一品红创立于2002年，是一家集药品研发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和 慢病药领域。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药 企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。 半年报披露，一品红2025上半年自主研发投入约9420.10万元，占公司营业收入的16.14%。截至报告披 露日，公司累计新增10个批件的注册证书，以新增产品通用名计算，公司新增获批数量持续位居医药企 业前列。 同时，一品红多渠道、多元化、全球范围内寻找和洽谈符合公司战略布局的项目合作授权，并积极开拓 CMO业务。报告期内，公司引进合作CMO项目2个，股权投资项目1个(含增资)，获得发明专利技术4 项。 截至报告披露日，一品红共有200个药品注册批件(含原料药登记号)，其中国家医保品种87个、国家基 药品种26个、国家中药保护品种1个。公司在儿童药领域现有27个注册批件，覆盖呼吸、抗感染、抗过 敏、消化等儿童常见病领域。在慢病药领域，公司现有67个注册批件，涵盖心脑血管疾病、泌尿系统疾 病、消化系统疾病等多个疾病治疗领域。 除儿童药和慢病药品 ...

自愿披露关于痛风创新药 AR882 全球Ⅲ期临床试验完成全部受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.公司合作在研的创新药 AR882 尚需在国内外开展Ⅲ期临床研究并经药品 审评部门审批通过后，方可上市销售,能否通过监管部门的最终批准、获批上市 及上市时间具有不确定性。AR882 目前尚未实现上市销售，未产生销售收入，对 公司近期业绩不会产生重大影响。 2.AR882 全球Ⅲ期临床试验进展对公司近期业绩不会产生重大影响。敬请广 大投资者理性投资，注意风险。 近日，一品红药业集团股份有限公司（以下简称"公司"）参股公司 Arthrosi Therapeutics,Inc.（以下简称"Arthrosi"）组织开展的 AR882（通用名：氘泊替 诺雷）胶囊用于治疗痛风和痛风石全球关键性Ⅲ期临床试验已完成全部受试者入 组。现将主要情况公告如下： 证券代码：300723 证券简称：一品红 公告编号：2025-056 一品红药业集团股份有限公司 公司始终秉承创新发展理念，坚持医药技术创新与高端药品研发，通过自主 研发、合资合作开 ...

智通财经APP讯，一品红(300723.SZ)发布2025年半年度报告，该公司营业收入为5.84亿元，同比减少 36.02%。归属于上市公司股东的净亏损为7354.22万元。归属于上市公司股东的扣除非经常性损益的净 亏损为1.08亿元。基本每股亏损为0.1628元。 2025上半年公司自主研发投入约9,420.10万元，占公司营业收入的16.14%。2025年至今公司新增产品注 册批件10个。 ...